T3	Participants 225 301	Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
T1	Participants 610 838	patients with recurrent or metastatic SCCHN and no prior systemic therapy for metastatic disease were randomized to pemetrexed (500 mg/m(2) ) plus cisplatin (75 mg/m(2) ; n = 398) or placebo plus cisplatin (75 mg/m(2) ; n = 397)
T2	Participants 2029 2093	patients with performance status 0 or 1 or oropharyngeal cancers
